Mayinglong Pharmaceutical Group Co., LTD.: history, ownership, mission, how it works & makes money

From a herbal eye-medicine workshop founded in Hebei in 1582 to a publicly traded healthcare group listed on the Shanghai Stock Exchange (600993) with a market capitalization of 12.44 billion CNY, Mayinglong Pharmaceutical Group Co., Ltd. blends centuries-old traditional Chinese medicine roots with modern pharma - relocating to Wuhan in 1956, earning 'Chinese Time-Honored Brand' status in 1997, going public in 2004 and launching its global bestseller, Mayinglong Hemorrhoid Ointment, abroad in 2015; today it operates a vertically integrated model across R&D, manufacturing, distribution and retail, holds 431.05 million shares outstanding with a trailing P/E of 21.70 and an EV/Revenue of 2.57, trades within a 52-week range of 23.42-31.46 CNY, reported trailing twelve‑month revenue of 3.77 billion CNY and net income of 571.60 million CNY, and has diversified into functional cosmetics, medical devices and health management services as it pursues innovation, sustainability and broader domestic and international reach-read on to explore its ownership, operations and revenue engines in detail.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): Intro

• 1582 - Founded by Ma Jintang in Hebei Province; origin in traditional ophthalmic remedies.
• 1956 - Operations relocated to Wuhan, Hubei Province; expanded into hemorrhoid treatments and broader pharmaceutical production.
• 1997 - Designated one of the first 'Chinese Time‑Honored Brands' by the Ministry of Commerce of the PRC.
• 2004 - Listed on the Shanghai Stock Exchange (ticker: 600993) - corporate modernization and access to capital markets.
• 2015 - Began systematic international distribution of Mayinglong Hemorrhoid Ointment, marking a push into global retail and OTC channels.
• By 2025 - Diversified into functional cosmetics, medical devices, and health management services, extending beyond traditional Chinese medicine (TCM) products.

• Publicly listed parent: Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) - free float on Shanghai Stock Exchange with institutional and retail shareholders.
• Major shareholders historically include founding-family related entities, state‑affiliated investment vehicles, and domestic institutional investors (holdings fluctuate with disclosures filed to the exchange).
• Operational subsidiaries focus on R&D, manufacturing (OTC & TCM formulations), medical devices, cosmetics, and health services delivery.

• Mission: Preserve and modernize traditional remedies while delivering accessible, evidence‑based healthcare products (see corporate statements and strategic plans).
• Strategic pillars: heritage TCM brands, OTC hemorrhoid and topical products, expansion into adjacent health & beauty, and selective overseas market entries.

• Flagship product: Mayinglong Hemorrhoid Ointment - core revenue driver in OTC channel, historically exported since 2015.
• Other portfolio items: ophthalmic TCM preparations, topical analgesics, wound care, functional cosmetics, and medical consumables/devices.
• R&D focus: formulation modernization, quality control, clinical validation for select indications, and development of cosmetic and device lines.
• Distribution: national retail pharmacy chains, hospital procurement for certain medical device lines, e‑commerce platforms, and export partners.

• OTC pharmaceuticals (hemorrhoid ointment, topical remedies) - largest single revenue source via pharmacies and e‑commerce.
• Prescription/medical channels - device and consumable sales to hospitals and clinics for specific product lines.
• Functional cosmetics and personal care - growing margin segment sold through retail and online channels.
• Health management services - pilots and localized service offerings contributing service revenues and cross‑selling opportunities.
• Exports/licensing - royalties and direct sales for international distribution of flagship products.

• Strong brand recognition in China for hemorrhoid and topical TCM products, leveraging heritage positioning and long consumer familiarity.
• Competes with domestic OTC specialists, TCM firms, and multinational consumer health companies in cosmetics and devices segments.
• Growth drivers: product line extensions (cosmetics, devices), export expansion for flagship products, and digital channel penetration.

• Manufacturing bases concentrated around Hubei (Wuhan) and other approved GMP facilities for pharmaceuticals and medical devices.
• Quality systems: compliance with national GMP and device regulatory standards; ongoing investments into automation and QC to support exports.

• Portfolio diversification into functional cosmetics and medical devices to reduce dependence on single‑product revenue.
• Internationalization of flagship products alongside local regulatory registrations in target markets.
• Digital and channel optimization: e‑commerce, cross‑border platforms, and partnerships to reach new consumer segments.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): History

• Founded: origins in local pharmaceutical operations (evolved into listed company)
• Listing: Shanghai Stock Exchange (ticker: 600993.SS)
• Core product areas: topical analgesics, wound care, consumer health products
• Strategy shifts: product standardization, scale manufacturing, retail/distribution partnerships

• Major shareholders: combination of institutional investors, corporate insiders, and retail investors (active market participation)
• Liquidity indicators: active daily trading within the 52-week range

• Mission: provide effective, affordable OTC and topical healthcare solutions for broad consumer access
• How it makes money:
  • Manufacturing and sale of proprietary OTC medicines and topical products
  • Wholesale distribution to pharmacies, hospitals, and retail chains
  • Licensing and export of branded products to selected international markets

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): Ownership Structure

• Mission: Deliver accessible, effective pharmaceutical and health-management solutions that raise population health standards.
• Values: Innovation, integrity, transparency, social responsibility, cultural preservation, and environmental sustainability.
• R&D focus: Integration of traditional Chinese medicine (TCM) practices with evidence-based modern therapies; ongoing investment in new-product development and safety/efficacy research.

• Revenue drivers: OTC TCM products, prescription pharmaceuticals, health management services, and consumer healthcare items.
• Manufacturing: Multiple GMP-certified facilities producing topical, oral, and specialty TCM formulations with environmentally-conscious process improvements.
• Distribution: National retail pharmacy channels, hospital procurement, e-commerce, and export markets.
• Value creation: Brand recognition rooted in a long heritage (company traces origins to 1582) plus R&D-led product extensions and recurring consumer demand for chronic/OTC remedies.

• Listed public company with a mix of institutional and retail shareholders; key controlling shareholders typically include founding groups and related parties (refer to latest A-share disclosures for current percentages).
• Corporate governance: Board and supervisory structures aligned with SSE listing rules; emphasis on transparency and compliance in disclosures and clinical/product safety reporting.
• CSR & environment: Active charitable programs for community health; ongoing initiatives to reduce manufacturing emissions and improve resource efficiency.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): Mission and Values

• Business model: Fully integrated from discovery through point-of-care-R&D, production, logistics and retail pharmacies-allowing capture of margin across the value chain.
• Manufacturing & quality: Multiple GMP-compliant plants with batch testing, QC labs and traceability systems to meet both domestic SFDA/NMPA standards and export regulatory requirements.
• Distribution network: Multi-channel reach via hospital procurement, retail pharmacies, franchise outlets and e-commerce platforms (third-party and proprietary online sales).
• Technology & automation: Investment in automated production lines, ERP and cold-chain logistics to raise throughput, lower per-unit costs and improve compliance.
• R&D focus: Dual-track R&D teams working on TCM formulations (topical plasters, ointments) and modern pharmaceuticals (OTC analgesics, wound care), including clinical trials and formulation optimization.
• Customer service & education: Medical affairs teams provide training, product literature and digital patient education tools for healthcare professionals and consumers.

• Proprietary TCM brands with long shelf-life and recurring OTC demand provide stable cash flow and higher gross margins relative to commodity generics.
• Vertical integration captures manufacturing and distribution margins; retail franchises and hospital supply contracts secure volume.
• Automation and scale reduce manufacturing cost per unit, improving gross margin by an estimated 150-300 bps versus manual lines.
• R&D pipeline and incremental product launches (new topical formulations, combination products) aim to sustain mid-single-digit revenue growth annually.

• Hospitals and institutional tenders: key for higher-volume prescription products and wound-care lines.
• Retail pharmacies and own-brand stores: primary channel for OTC TCM products and consumer-facing lines.
• Online marketplaces and direct-to-consumer platforms: growing share, accounting for double-digit percentage growth year-over-year.
• Export partnerships: selective international sales to neighboring Asian markets and distributors for specific product lines.

• Balanced portfolio: maintaining legacy TCM formulations while developing modernized delivery systems (patches, sustained-release topical systems).
• Clinical investment: focused, relatively modest clinical trial budgets targeting incremental label expansions and evidence generation for hospital adoption.
• Intellectual property: patents on formulation/process for flagship products, trademarks for core brands; IP strategy emphasizes defensive protection in primary markets.

• Regulatory scrutiny and changing NMPA standards can increase compliance costs and time-to-market for new products.
• Competition from domestic generics and larger pharmaceutical groups pressures pricing for certain OTC and prescription segments.
• Supply chain concentration for specific herbal raw materials exposes production to agricultural and sourcing variability.
• R&D scalability: shifting from traditional formulation updates to higher-cost, modern drug development could require increased capital and longer payback periods.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): How It Works

• Core product sales: flagship topical and OTC pharmaceuticals (notably Mayinglong Hemorrhoid Ointment) sold through retail pharmacies, hospital channels, and e-commerce.
• Adjacent healthcare products: cough remedies, skin injury and wound care medications, and related consumables.
• Consumer & services: functional cosmetics, health management services, and post-sales support programs to increase lifetime customer value.
• Medical devices & distribution: wholesale supply of allied healthcare products and devices to hospitals, clinics and distributors.
• R&D-driven pipeline: internal drug formulation and new product launches to expand market share and margins.

• High-margin flagship SKU: Mayinglong Hemorrhoid Ointment is a perennial cash generator both domestically and internationally, anchoring brand recognition and trade terms with pharmacies and distributors.
• Channel diversification: revenue from retail pharmacies, hospital procurement, e-commerce and export markets smooths seasonality and concentration risk.
• Product lifecycle leverage: mature OTC lines provide steady cash flows while newer Rx/medical device launches aim at higher ASPs (average selling prices) and longer-term growth.
• R&D investment converts into patent-protected formulations and line extensions that raise unit economics and brand premium over time.

• Retail pharmacy network: national coverage with trade discounts and promotion-driven volume.
• Hospital procurement: tender and institutional sales for wound-care and device lines, often larger volumes and longer payment cycles.
• E‑commerce & cross-border: direct-to-consumer sales domestically and exports of branded SKUs, improving gross margin via reduced intermediaries.
• Distributor partnerships: regional distributors extend reach to lower-tier cities and overseas markets with negotiated margins.

• Incremental launches lift average selling price and extend portfolio shelf life.
• R&D-to-sales ratio (typical ~3-6%) balances near-term profit with long-run competitiveness.
• New formulations and cosmetic extensions create cross-sell opportunities within existing retail and e‑commerce channels.

• Manufacturing scale lowers per-unit cost for mass-market OTC products, preserving margin advantage.
• Brand equity in hemorrhoid treatment supports licensing, exports and private-label discussions.
• Data from health management services feeds product development priorities and targeted marketing.

Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): How It Makes Money

• Core product sales: Mayinglong Hemorrhoid Ointment and related topical remedies sold through pharmacies, hospitals and retail channels.
• Consumer healthcare & OTC portfolio: creams, sprays and over‑the‑counter products leveraging brand recognition.
• Functional cosmetics: new product lines targeting skin health and wellness consumers.
• Health management services: value‑added services and programs that cross‑sell products and build recurring revenue.
• Exports & international distribution: licensing, distribution agreements and direct exports to overseas markets.

• Market position & outlook: Strong domestic brand equity from its flagship product supports steady cash flow; strategic expansion into cosmetics and health services aims to capture higher‑growth consumer health demand.
• R&D & innovation: Continued investment in R&D is expected to sustain product pipeline and margin improvement through premiumized offerings.
• Geographic strategy: A dual focus on deepening domestic penetration while expanding international channels supports diversified revenue streams and future growth.